Physician profile
Michael Ruisi
NPI 1750515292
$2,302.12
in general payments reported to CMS, 2019-2025
29 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $235 · 2021: $353 · 2022: $532 · 2023: $275 · 2024: $293 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $247.09 | 2022 | |
| Amgen INC. | $246.95 | 2021-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $189.08 | 2020 | |
| Penumbra, INC. | $174.38 | 2024-2025 | Indigo System, Penumbra System |
| Tosoh Bioscience, INC. | $169.00 | 2019 | |
| Medtronic, INC. | $162.93 | 2021-2025 | Symplicity G3, Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.34 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $100.45 | 2021-2023 | Nexletol |
| W. L. Gore & Associates, INC. | $97.79 | 2019-2020 | |
| Boston Scientific Corporation | $79.92 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.82 | 2021-2024 | Brilinta |
| Abbott Laboratories | $78.11 | 2020-2023 | Aveir |
| Cvrx, INC. | $51.16 | 2024-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $48.97 | 2021-2024 | Verquvo |
| Novo Nordisk INC | $48.03 | 2022-2025 | Ozempic |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $46.91 | 2024 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $41.62 | 2023-2025 | Camzyos, Eliquis |
| Welch Allyn | $38.13 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.28 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.83 | 2022-2023 | Jardiance |
| Cmp Pharma, INC. | $29.88 | 2023 | Norliqva, Atorvaliq, Carospir |
| Inari Medical, INC. | $27.51 | 2022 | |
| Bardy Diagnostics, INC. | $27.50 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $24.80 | 2024 | Arcalyst |
| Philips North America LLC | $24.34 | 2025 | Ecc Solutions |
| Pfizer INC. | $21.43 | 2022 | |
| Bard Peripheral Vascular, INC. | $20.03 | 2023 | Venovo |
| Novartis Pharmaceuticals Corporation | $13.47 | 2024 | |
| Teleflex LLC | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ruisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.